Chemoprotection by sulforaphane: keep one eye beyond Keap1.

Area of Science:

• Phytochemistry
• Cancer Biology
• Molecular Pharmacology

Background:

• Sulforaphane (SFN) is a cruciferous vegetable phytochemical known for chemopreventive properties.
• Historically recognized for inducing Phase 2 and inhibiting Phase 1 enzymes, SFN's mechanisms are more diverse.
• Recent research highlights SFN's broader biological activities beyond the Nrf2/Keap1 pathway.

Purpose of the Study:

• To review established and emerging mechanisms of sulforaphane's chemoprotective and therapeutic potential.
• To explore SFN's role in various stages of carcinogenesis, including post-initiation.
• To highlight SFN's promise in treating inflammation-associated and pathogen-related cancers.

Main Methods:

• Literature review of studies on sulforaphane's biological activities.
• Analysis of SFN's effects on enzyme activity, cell cycle, apoptosis, and epigenetic modifications.
• Examination of SFN's therapeutic implications in preclinical and clinical contexts.

Main Results:

• SFN modulates the Nrf2/Keap1 pathway and exhibits other anticancer effects.
• SFN induces cell cycle arrest, apoptosis, and inhibits histone deacetylase activity.
• SFN demonstrates potential as a 'suppressing' agent in later carcinogenesis stages and for treating specific cancer types.

Conclusions:

• Sulforaphane possesses multifaceted mechanisms contributing to its chemopreventive and therapeutic potential.
• SFN's activity extends beyond blocking mechanisms, showing promise in cancer suppression.
• Further research into SFN's later-stage carcinogenesis mechanisms is warranted for optimizing cancer therapy.